Table 2. Univariable and multivariable logistic regression analysis of patient demographic and clinical characteristics at 5-year mortality.
| Variable | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Sex (male) | 0.966 (0.599–1.556) | 0.886 | ||
| Age at mRCC diagnosis | 1.014 (0.995–1.033) | 0.162 | ||
| ECOG performance status ≥1 | 1.330 (0.759–2.326) | 0.319 | ||
| Neutrophil/lymphocyte ratio ≥4 | 4.160 (1.890–9.157) | <0.001 | 4.227 (1.958–9.127) | <0.001 |
| Synchronous metastasis | 3.245 (2.180–4.831) | <0.001 | 3.365 (2.274–4.981) | <0.001 |
| No. of metastasis ≥2 | 1.415 (0.953–2.103) | 0.085 | ||
| Albumin <3.0 g/dL | 2.121 (1.087–4.140) | 0.028 | 2.146 (1.125–4.093) | 0.021 |
| Corrected Ca >9.2 mg/dL | 1.434 (0.721–2.852) | 0.305 | ||
| Hb (<LLN, male 13 g/dL, female 11.5 g/dL) | 1.802 (1.188–2.733) | 0.006 | 1.830 (1.223–2.739) | 0.003 |
| Platelet (>ULN) | 0.453 (0.151–1.365) | 0.160 | ||
| WBC (>ULN) | 1.267 (0.565–2.837) | 0.566 | ||
OR, odds ratio; CI, confidence interval; mRCC, metastatic renal cell carcinoma; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; LLN, lower limit of normal; ULN, upper limit of normal; WBC, white blood cell.